SET Domain Containing 7: A Tissue-Based Epigenetic Biomarker for Early Detection of Colorectal Cancer

Area of Science:

• Epigenetics
• Molecular Oncology
• Biomarker Discovery

Background:

• Methyltransferase proteins, like SET Domain Containing 7 (SETD7), are implicated in carcinogenesis via epigenetic mechanisms.
• Early detection of colorectal cancer (CRC) is crucial due to poor survival rates.
• SETD7's role in CRC initiation warrants investigation as a potential early diagnostic biomarker.

Purpose of the Study:

• To investigate SETD7 expression in metastatic and nonmetastatic CRC tissues versus healthy tissues.
• To evaluate SETD7's potential as an early diagnostic biomarker for colorectal cancer.
• To correlate SETD7 expression levels with CRC stage and progression.

Main Methods:

• Bioinformatic analysis of SETD7 gene expression using the UALCAN database.
• Quantitative real-time PCR (RT-qPCR) to measure SETD7 expression in 80 colorectal tumor and adjacent normal tissues.
• Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic accuracy.

Main Results:

• SETD7 expression was significantly increased in colorectal tumor tissues compared to normal tissues (p = 0.0001).
• This elevation was statistically significant in nonmetastatic tumor tissues (p = 0.0001).
• ROC analysis indicated SETD7 expression is a good biomarker for distinguishing tumor from normal tissue (AUC = 0.85).

Conclusions:

• Elevated SETD7 gene expression serves as a potential epigenetic marker for CRC.
• SETD7 can be utilized for tissue-based prognosis and screening in early-stage CRC.
• This finding supports SETD7's utility in early colorectal cancer detection and management.